J2501 Paricalcitol Injection HCPCS Reimbursement

HCPCS Level II code J2501 designates a 1 mcg injection of paricalcitol, an active vitamin D analog commonly used in the management of secondary hyperparathyroidism among patients with chronic kidney disease. As a medication-specific HCPCS Level II code, J2501 is used on medical claims to identify and report the paricalcitol product administered. Nationally, accurate coding of injectable therapies like paricalcitol affects drug utilization reporting, payer coverage determinations, and medication billing consistency across outpatient infusion clinics and dialysis centers.

Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for paricalcitol injections, the typical sites of service where J2501 is billed, and the payer landscape that governs coverage and billing practices. The publication also summarizes available benchmarks and policy considerations relevant to injectable specialty medications, clarifies coding usage for claims submissions, and highlights areas where payers commonly set coverage criteria or prior authorization requirements.

Data not available in the input for specific associated taxonomies, ICD-10 diagnoses, and related codes is noted where applicable.

Billing Code Overview

HCPCS Level II code J2501 represents an injection of paricalcitol, 1 mcg. This code denotes administration of the active vitamin D analog paricalcitol for indications such as management of secondary hyperparathyroidism in patients with chronic kidney disease. The service type is injectable medication administration, and the typical site of service is outpatient infusion/clinic or dialysis center.

Data not available in the input.

Clinical Context

A typical patient is an adult with end-stage renal disease (ESRD) on chronic hemodialysis who presents for routine in-center dialysis management and laboratory-directed treatment of secondary hyperparathyroidism. Paricalcitol (J2501) is administered intravenously by dialysis nursing staff during or immediately after a dialysis session to suppress elevated parathyroid hormone (PTH) levels when vitamin D analog therapy is indicated. The clinical workflow includes review of recent labs (serum calcium, phosphorus, PTH), confirmation of dosing per nephrology orders, verification of venous access and line compatibility, preparation of the unit dose syringe or vial, documentation of lot and expiration, administration via IV push or infusion per facility protocol, monitoring for immediate adverse effects (hypotension, hypersensitivity), and recording the administration in the dialysis record and medication administration record for billing and quality reporting.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	Use when part of the paricalcitol dose is discarded and the discarded amount must be reported for payer tracking.
`JZ`

Taxonomy Code	Specialty	Notes
`2080P0207X`	Nephrology	Nephrologists order and manage paricalcitol for secondary hyperparathyroidism in CKD/ESRD.
`332B00000X`	Dialysis Facility/Center	Dialysis nursing staff administer IV paricalcitol during hemodialysis sessions.
`163W00000X`	Nurse Practitioner	NPs in nephrology clinics may prescribe and manage vitamin D analog therapy.
`207R00000X`	Internal Medicine	Hospitalists or internists manage inpatient dosing when ESRD patients are hospitalized.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E83.51`	Secondary hyperparathyroidism of renal origin	Primary indication for paricalcitol to suppress elevated PTH in CKD/ESRD.
`N18.6`	End stage renal disease	Typical patient population receiving paricalcitol during dialysis.
`N18.5`	Chronic kidney disease, stage 5	Advanced CKD requiring management of mineral and bone disorder with vitamin D analogs.
`E83.50`	Disorders of phosphorus metabolism, unspecified	Electrolyte derangements that affect PTH management and indicate vitamin D analog therapy.
`D63.1`	Anemia in chronic kidney disease	Common comorbidity in ESRD patients receiving dialysis and adjunctive therapies.
`R29.6`	Recurrent falls	Clinical relevance for monitoring calcium and adverse events during therapy.
`E83.52`	Secondary hyperparathyroidism due to nonrenal disorders	Alternate etiology; less common but relevant differential.
`M81.0`	Age-related osteoporosis without current pathological fracture	Bone disease that may coexist and influence vitamin D analog use.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration infusion, 1 hour; requiring infusion pump	Administered when intravenous infusion therapy is used; rarely used for short IV push injections like paricalcitol but may apply if combined with other infusion therapies.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used when injections are administered but is not appropriate for IV injections administered during dialysis; included as a commonly billed injection CPT.
`90785`	Immune globulin administration, intravenous, for immune modulators (single or multiple)	Data not available in the input.
`99213`	Office or other outpatient visit, established patient, low to moderate complexity	Evaluation and management visit for medication management and dose adjustment of paricalcitol by the ordering clinician.
`90899`	Unlisted procedure, psychiatric	Data not available in the input.

OpenPayer

Summary & Overview

HCPCS J2501: Paricalcitol Injection, 1 mcg